Literature DB >> 22206816

Riluzole and gabapentinoids activate glutamate transporters to facilitate glutamate-induced glutamate release from cultured astrocytes.

Masaru Yoshizumi1, James C Eisenach, Ken-ichiro Hayashida.   

Abstract

We have recently demonstrated that the glutamate transporter activator riluzole paradoxically enhanced glutamate-induced glutamate release from cultured astrocytes. We further showed that both riluzole and the α(2)δ subunit ligand gabapentin activated descending inhibition in rats by increasing glutamate receptor signaling in the locus coeruleus and hypothesized that these drugs share common mechanisms to enhance glutamate release from astrocytes. In the present study, we examined the effects of riluzole and gabapentin on glutamate uptake and release and glutamate-induced Ca(2+) responses in primary cultures of astrocytes. Riluzole and gabapentin facilitated glutamate-induced glutamate release from astrocytes and significantly increased glutamate uptake, the latter being completely blocked by the non-selective glutamate transporter blocker DL-threo-β-benzyloxyaspartic acid (DL-TBOA). Riluzole and gabapentin also enhanced the glutamate-induced increase in intracellular Ca(2+) concentrations. Some α(2)δ subunit ligands, pregabalin and L-isoleucine, enhanced the glutamate-induced Ca(2+) response, whereas another, 3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid (ABHCA), did not. The enhancement of glutamate-induced intracellular Ca(2+) response by riluzole and gabapentin was blocked by the DL-TBOA and an inhibitor of Na(+)/Ca(2+) exchange, 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiurea (KB-R7943). Gabapentin's enhancement of Ca(2+) increase was specific to glutamate stimulation, as it was not mimicked with stimulation by ATP. These results suggest that riluzole and gabapentin enhance Na(+)-glutamate co-transport through glutamate transporters, induce subsequent Ca(2+) influx via the reverse mode of Na(+)/Ca(2+) exchange, and thereby facilitate Ca(2+)-dependent glutamate release by glutamate in astrocytes. The present study also demonstrates a novel target of gabapentinoid action in astrocytes other than α(2)δ subunits in neurons.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206816      PMCID: PMC3268950          DOI: 10.1016/j.ejphar.2011.12.015

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

Review 1.  Mechanisms of glutamate release from astrocytes.

Authors:  Erik B Malarkey; Vladimir Parpura
Journal:  Neurochem Int       Date:  2007-06-26       Impact factor: 3.921

2.  (L)-Phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats.

Authors:  James J Lynch; Prisca Honore; David J Anderson; William H Bunnelle; Kathleen H Mortell; Chengmin Zhong; Carrie L Wade; Chang Z Zhu; Hongyu Xu; Kennan C Marsh; Chih-Hung Lee; Michael F Jarvis; Murali Gopalakrishnan
Journal:  Pain       Date:  2006-06-14       Impact factor: 6.961

3.  Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation.

Authors:  Chun-Ying Li; Xiu-Lin Zhang; Elizabeth A Matthews; Kang-Wu Li; Ambereen Kurwa; Amin Boroujerdi; Jimmy Gross; Michael S Gold; Anthony H Dickenson; Guoping Feng; Z David Luo
Journal:  Pain       Date:  2006-06-09       Impact factor: 6.961

4.  Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery.

Authors:  Ken-Ichiro Hayashida; Sophia DeGoes; Regina Curry; James C Eisenach
Journal:  Anesthesiology       Date:  2007-03       Impact factor: 7.892

5.  Na+ entry via glutamate transporter activates the reverse Na+/Ca2+ exchange and triggers Ca(i)2+-induced Ca2+ release in rat cerebellar Type-1 astrocytes.

Authors:  Héctor Rojas; Claudia Colina; Magaly Ramos; Gustavo Benaim; Erica H Jaffe; Carlo Caputo; Reinaldo DiPolo
Journal:  J Neurochem       Date:  2007-03       Impact factor: 5.372

6.  Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.

Authors:  Jan Hendrich; Alexandra Tran Van Minh; Fay Heblich; Manuela Nieto-Rostro; Katrin Watschinger; Jörg Striessnig; Jack Wratten; Anthony Davies; Annette C Dolphin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

7.  Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.

Authors:  Elena Fumagalli; Marcella Funicello; Thomas Rauen; Marco Gobbi; Tiziana Mennini
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

8.  Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice.

Authors:  Masahiro Irifune; Nobuhito Kikuchi; Takuya Saida; Tohru Takarada; Yoshitaka Shimizu; Chie Endo; Katsuya Morita; Toshihiro Dohi; Tomoaki Sato; Michio Kawahara
Journal:  Anesth Analg       Date:  2007-06       Impact factor: 5.108

Review 9.  Glutamate-mediated neuronal-glial transmission.

Authors:  Alexei Verkhratsky; Frank Kirchhoff
Journal:  J Anat       Date:  2007-05-15       Impact factor: 2.610

Review 10.  Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.

Authors:  Anthony Davies; Jan Hendrich; Alexandra Tran Van Minh; Jack Wratten; Leon Douglas; Annette C Dolphin
Journal:  Trends Pharmacol Sci       Date:  2007-04-02       Impact factor: 14.819

View more
  15 in total

Review 1.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

2.  Effect of glutamate and riluzole on manganese-induced apoptotic cell signaling in neuronally differentiated mouse P19 Cells.

Authors:  Jerome A Roth; Swetha Sridhar; Steven T Singleton
Journal:  Neurochem Int       Date:  2012-04-21       Impact factor: 3.921

Review 3.  Chronic treatment with anti-bipolar drugs causes intracellular alkalinization in astrocytes, altering their functions.

Authors:  Dan Song; Baoman Li; Enzhi Yan; Yi Man; Marina Wolfson; Ye Chen; Liang Peng
Journal:  Neurochem Res       Date:  2012-07-28       Impact factor: 3.996

4.  Riluzole partially rescues age-associated, but not LPS-induced, loss of glutamate transporters and spatial memory.

Authors:  Holly M Brothers; Isabelle Bardou; Sarah C Hopp; Roxanne M Kaercher; Angela W Corona; Ashley M Fenn; Jonathan P Godbout; Gary L Wenk
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-25       Impact factor: 4.147

5.  Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms.

Authors:  Takashi Suto; Amie L Severino; James C Eisenach; Ken-ichiro Hayashida
Journal:  Neuropharmacology       Date:  2014-02-01       Impact factor: 5.250

Review 6.  From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders.

Authors:  Gerard Sanacora; Mounira Banasr
Journal:  Biol Psychiatry       Date:  2013-06-15       Impact factor: 13.382

7.  Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases.

Authors:  B Di Benedetto; R Rupprecht
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

8.  Gabapentin loses efficacy over time after nerve injury in rats: role of glutamate transporter-1 in the locus coeruleus.

Authors:  Masafumi Kimura; James C Eisenach; Ken-Ichiro Hayashida
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

9.  Inhibition of astrocyte activation is involved in the prevention of postoperative latent pain sensitization by ketamine and gabapentin in mice.

Authors:  Elizabeth Romero-Alejo; Margarita M Puig; Asunción Romero
Journal:  J Pharmacol Pharmacother       Date:  2016 Jan-Mar

Review 10.  A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue.

Authors:  Maha Elsayed; Pierre J Magistretti
Journal:  Front Cell Neurosci       Date:  2015-12-16       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.